Protection from Brand Infection: Marketers Must Take Control of Their Brands, Especially Online
In response to concerns about the growing range of threats to brand value and the sheer volume of brand hijacking incidents, the CMO Council set out to assess the challenges marketers face as stewards of their brands. The result is Protection from Brand Infection, a seminal authority leadership report that outlines the proliferating threat-scape that marketers face and reveals how marketers are struggling to understand and measure the impact brand intrusions have on their second most valuable asset, their customer.
Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway
Arnold Friede, counsel to the law firm McDermott Will & Emery LLP, and former Senior Counsel at Pfizer, believes that there is an opportunity now to make a strong and compelling argument for the adoption of rational regulatory policies by the FDA that address the unique features not only of sponsored links, but of other kinds of new communication tools, such as social media.
The New PhRMA Code and Beyond: Federal & State Laws are Eclipsing Self-Regulation
At a recent ExL Pharma conference industry leaders from pharma and the vendor community reviewed the impact on
From Nalty to “Nalts”: The Transformation of a Pharma Marketing Director into a “Viral...
While Kevin Nalty worked during the day as Con-sumer Product Director at Merck, where he marketed Propecia, at night and on weekends he was making comedic videos for YouTube -- a few of which were critical of drug ads, marketing, and medical conditions. Read this interesting story and learn how not to get fired doing new media marketing.
Pharma Marketing News Vol. 8, #4
Welcome to the April 2009 issue of Pharma Marketing News.
Pharma Marketing News Vol. 8, #4
Welcome to the April 2009 issue of Pharma Marketing News.
Developing Guidelines for Pharma’s Use of the Internet & Social Media: Whatever! A Call...
Shouldn't we make sure that when it comes time for the FDA to actually create a guidance document on social media that it does it with input from ALL stakeholders? Survey results.
The Empowered Patient: What It Means for Pharma Marketers
This article presents a case for the drug industry to adopt a patient-centric model in which pharma companies can develop unique expertise in decoding the behavior, needs, motivations of empowered patients and then use this knowledge as the basis for helping healthcare professionals and payers to put into place programs that achieve better patient outcomes.
Socially Challenged Pharma: How Ready is Pharma to Engage In Social Media?
This article summarizes the recent Digital Pharma Europe congress where it was the time right to see that European pharma marketers are also interested in new/social/digital media in pharma, but may be more constrained by regulators than their brethern in the US.
Report from the Social Pharmer “Unconference”: Sowing Seeds of Social Media Change?
This article summarizes key presentations made at the April 21, 2009, Social Pharmer 'unconference' where leading pahram social media proponents presnted ideas on how the industry can overcome the barriers.
